CDKL5 and tuberous sclerosis: Further, it is also an approved drug by USFDA in treating conditions such as idiopathic epilepsy, CDKL5 deficiency, resistant Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.